Dihexa

Also known as: PNB-0408, N-hexanoic-Tyr-Ile-(6) aminohexanoic amide

**Mechanism of Action** Dihexa (PNB-0408) is a synthetic small peptide derived from angiotensin IV, designed to enhance hepatocyte growth factor (HGF) signaling through its receptor c-Met. By potentiating HGF/c-Met pathway activity, Dihexa promotes synaptogenesis—the formation and stabilization of new synaptic connections—without directly binding to angiotensin receptors. This mechanism is distinct from traditional nootropics, as it targets structural plasticity rather than acute neurotransmitter modulation. **Key Research Findings** Preclinical studies demonstrate Dihexa’s ability to reverse cognitive deficits in rodent models of aging, Alzheimer’s disease, and traumatic brain injury. In scopolamine-induced amnesia models, Dihexa restored spatial memory and object recognition to levels comparable to young controls. Chronic administration increased dendritic spine density in the hippocampus and prefrontal cortex, correlating with improved performance in Morris water maze and novel object recognition tasks. Notably, Dihexa showed no overt toxicity or seizure liability in animal studies, though long-term safety data remain limited. **Clinical Relevance** Dihexa remains in preclinical development, with no human trials completed. Its potential applications include age-related cognitive decline, Alzheimer’s disease, and traumatic brain injury recovery. However, the absence of pharmacokinetic and safety data in humans precludes clinical translation. The peptide’s ability to induce synaptogenesis offers a novel therapeutic avenue, but its clinical utility depends on future validation of efficacy and tolerability in human subjects. For research purposes only — not medical advice.

Key data

Research & studies

Frequently asked questions

Related peptides